Navigation Links
Scientists Spot Real 'Smoking Gun' in Prostate Cancer
Date:5/21/2010

Gene fusion may be behind disease, not androgen receptors, study suggests

FRIDAY, May 21 (HealthDay News) -- The primary cause of prostate cancer could be the fusion of two genes and the subsequent abnormal prostate cell growth that results when receptors for the hormone androgen get blocked, a new study reveals.

The implication is that standard efforts to treat the disease by targeting the androgen receptors might be missing the real "smoking gun," a University of Michigan Comprehensive Cancer Center team suggests.

"We need to begin to think about targeting prostate cancer by targeting the gene fusion, and not confining our approaches to androgen receptors," study author Dr. Arul Chinnaiyan, director of the Michigan Center for Translational Pathology, said in a news release. "If we're going to find a more durable therapy, we need to get at the gene fusion."

Chinnaiyan and his colleagues report their findings in the May 18 issue of Cancer Cell.

The authors note that typical prostate cancer treatments focus on drugs that attempt to slow production of androgen, the male hormone that regulates healthy prostate growth. However, such efforts usually become less effective over time as cancer cell resistance mounts, making recurrent cancer much less amenable to similar treatments.

But having earlier identified a so-called "on switch" for prostate cancer development in the form of the initial fusion of a prostate gene with a cancer-causing gene, Chinnaiyan and colleagues now have launched a new investigation into what happens post-fusion.

By using high-tech genetic mapping techniques, the research team found that once fusion takes place, androgen receptors get blocked, in turn cutting off normal prostate cell growth while permitting cancer to spread.

"Our study shows the underlying problem in prostate cancer is the presence of a gene fusion, not the androgen receptor," Chinnaiyan said in the news release. "In many contexts, androgen signaling is actually a good thing, but the presence of the gene fusion blocks androgen receptor signaling, which alters normal prostate cell development. While current treatments for advanced prostate cancer are focused on hormone deprivation and are quite effective, at least initially, future therapies need to be developed that target the prostate cancer gene fusion."

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.



-- Alan Mozes



SOURCE: Cancer Cell, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover the molecular heart of collective behavior
2. Scientists Map Genetic Codes of Human Microbes
3. Scientists find protein spurs spread of prostate cancer
4. What to Read on World Ocean Day: Scientists and Non Profits Herald New Eco-Thriller Eye of the Whale
5. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
6. Wistar scientists explain the persistence of melanoma through dynamic stemness
7. Mass. Eye and Ear receives NEI grant renewal for growing clinical/scientists
8. Scientists Map Neanderthal Genome
9. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
10. Scientists Unravel Secret of HIV Resistance
11. A century-old puzzle comes together: Scientists ID potential protein trigger in lung disease sarcoidosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... At Hallmark Nameplate, their commitment to quality is what sets ... ISO 13485. This certification is another way they are making constant strides to provide ... they need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... problems ranging from gum disease to enamel erosion, and those dental problems can ... Department of Public Health, many pregnant women are failing to get the dental ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone ... choose the best drug option for each patient. Dentists have several general anesthesia alternatives ... outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and researchers ... those who desire a more intimate review and analysis of its highlights, a novel ... Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by Kathy ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017   Spotlight Innovation Inc. (OTCQB: ... in the second quarter of 2017, to launch ... to provide relief from chronic pain, is a ... was developed under a licensing agreement with Dr. ... from snake venom. Additionally, Caretta Therapeutics has signed ...
(Date:1/18/2017)... , Jan 18, 2017 Research and Markets ... Vomiting Drugs Market 2017-2021" report to their offering. ... The global CINV drugs ... 2017-2021. Global Thoracic Surgery Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/18/2017)... -- In China , we say Health ... of China,s Healthy Strategy originates. 2016 ... Economic and Social Development of the People,s Republic ... state council of the People,s Republic of China ... development plan, identifying medical devices as one of the main ...
Breaking Medicine Technology: